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ABSTRACT 
The risk of transfusion-transmitted malaria is a major concern in many countries. This 
study investigated the prevalence of malaria antibodies and parasitemia in eligible blood 
donors in Jiangsu, in Eastern China. Malaria antibodies were detected in 2.13% of the 
704 plasma samples studied. We found that the prevalence of malaria antibodies was not 
significantly correlated with gender, occupation and frequency of donation, but it increased 
with age. No Plasmodium was observed in red blood cells and no Plasmodium DNA was 
detected in any of the antibody-positive samples. The prevalence of malaria antibodies was 
not higher than expected in Eastern China. 
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Malaria is a major cause of morbidity and mortality worldwide and is caused 
by parasites of the Plasmodium species, transmitted to humans through the bite of 
infected female Anopheles mosquitoes. It is one of the most common diseases in 
the world; more than half of the world’s population lives in regions where malaria 
is endemic. Each year, between 300 and 500 million cases are reported globally, 
resulting in more than 1 million deaths, most of them among the younger population1. 
In 1955, it was estimated that malaria was endemic to 70-80% of the counties in 
China; then malaria infection was inhibited by more than 80% after the launch of 
a national malaria control program2. China has implemented a national malaria 
elimination strategy to achieve complete elimination by 20203. In 2010, it was 
calculated that approximately half of the Chinese population lives in areas with no 
risk of malaria, 1% lives in high-risk areas, such as the Yunnan Province, and the 
remaining lives in low-risk areas, such as the Jiangsu province4.
However, the risk of malaria transmission from other endemic settings continues 
to increase due to the population mobility for travel, business and work. This 
constitutes a major challenge for malaria elimination in China. Between 2010 and 
2014, a number of cases of imported Plasmodium falciparum were reported from all 
the provinces of China, largely due to import from other countries, especially from 
countries in Africa where P. falciparum is very prevalent5. A number of Chinese 
workers also travel as laborers to Africa, where many countries are endemic for 
malaria; this trend has further increased the number of potential malaria-infected 
donors in China. No autochthonous cases of malaria have been reported in the 
Jiangsu province since 19986; sporadic cases of imported malaria, mostly from 
Africa and Southeast Asia, have been reported in recent years. This has led to an 
increase in the proportion of blood donors at risk for malaria. In August 2013, a 
transfusion-transmitted malaria (TTM) case caused by P. falciparum was reported in 
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Jiangsu Province Blood Center for the first time. The blood 
donor was a worker who recently returned from Kenya 
and once had malaria. He later admitted to concealing his 
medical history in order to know whether he had recovered 
enough to donate blood. 
This study was designed to determine the prevalence of 
malarial antibodies among blood donors, aiming to alert the 
appropriate authorities to the risk of TTM.
The present study was performed from July to 
September 2015. Prospective donors were examined and 
given a questionnaire including their travel history. They 
were then screened for alanine aminotransferase (ALT), 
syphilis, and hepatitis B surface antigens (HBsAg) at 
different collection sites. The collected blood samples were 
screened by two different reagents for ALT, HIV, HBsAg, 
HCV, and syphilis; the negative samples were further 
subjected to a nucleic acid test (NAT) for HIV, HBV and 
HCV. We selected plasma samples from eligible blood 
donors (negative for the routine screening above and no 
self-reported malaise), whose blood samples could be used 
clinically for malaria antibodies screening. 
All samples were tested for malaria antibodies using 
the Pan Malaria Antibody CELISA kit (CeLLabs, Sydney, 
Australia), as recommended by the manufacturer. The kit 
uses a sandwich ELISA for the detection of specific IgG 
antibodies against P. falciparum, P. vivax, P. malariae, and 
P. ovale in serum and plasma samples. Results were defined 
as sample-to-cut-off (S/CO) ratios. The test package insert 
indicated a gray zone between 0.8 and 1.0, which was 
extended to between 0.5 and 1.0 by our testing laboratory. 
All initially reactive samples were retested in duplicate to 
determine repeated reactivity.
Whole blood samples from malaria antibody-reactive 
samples were delivered to a clinical lab in a local hospital. 
Thick and thin blood films stained with Giemsa were 
prepared and microscopy readings were performed by 
an expert to detect parasitemia. DNA was extracted from 
0.2 mL of whole blood of all the reactive samples using 
a QIAamp® DNA Blood Mini Kit (Qiagen Inc. Hilden, 
Germany), according to the manufacturer’s instructions. 
A genus-specific primer pair and four species-specific 
primer pairs (targeting P. falciparum, P. vivax, P. malariae, 
and P. ovale) for nested PCR assay were designed based 
on the genes for the small-subunit ribosomal RNA of 
Plasmodium; the thermal cycler conditions used were as 
described previously7. 
Informed consents were obtained before blood donation. 
The study was approved by the Ethical Committee of 
Jiangsu Province Blood Center (serial number 2014-11).
Among the 704 blood samples studied, 44 were from 
foreign citizens or workers in foreign companies, 270 
from workers returned from malaria-endemic provinces, 
206 from university students from tropical or subtropical 
regions of China, and 184 from local Jiangsu citizens. 
Malaria antibodies were detected in 2.84% (20/704) of - 
blood samples, including seven gray zone samples. Positive 
samples were retested showing that 15 (2.13% of total) were 
confirmed positive for malaria antibodies. The S/CO values 
of 12 of these positive samples were between 1.03 and 1.79, 
while one had a value of 2.37 and two had 0.9 in the gray 
zone. Eight of them were mobile workers, five were local 
citizens, one worked in a foreign company, and one was a 
foreign university student from Africa. The prevalence of 
malaria antibodies in subjects from foreign countries and 
companies was the highest one (4.55%).
We found no significant correlation between the 
expression of malaria antibodies and several parameters, 
including genders (χ2 = 0.01, P = 0.9203), occupation 
(χ2 = 2.75, P = 0.0973), or donation frequencies (χ2 = 0.22, 
P = 0.6390); however, the prevalence of malaria antibodies 
was found to increase with the element of age. Blood donors 
aged 46-60 years had the highest prevalence of malaria 
antibodies, and this prevalence was significantly different 
from that in other age groups (χ2 = 10.29, P = 0.0013) 
(Table 1).
Table 1 - Prevalence of malaria antibodies and demographic 
characteristics of blood donors
Donor characteristics Blood donors (N)
Malarial 
antibodies 
(N)
Percent 
(%)
Gender
Male 502 10 1.99
Female 202 5 2.48
Age(years)
18- 45 602 8 1.33
18- 25 224 2 0.89
26- 35 205 2 0.98
36- 45 173 4 2.31
46-60 102 7 6.86
Occupation
University student 206 1 (foreigner) 0.49
Worker 498 14 2.81
Foreign countries 44 2 4.55
Other provinces 270 8 2.96
Local province 184 4 2.17
Donation Frequency
First 552 13 2.36
Repeat 152 2 1.32
Total 704 15 2.13
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No Plasmodium parasites were detected in red blood 
cells by microscopy and none of the samples tested positive 
for Plasmodium DNA as assessed by nested PCR.
TTM cases were often reported worldwide. Blood 
donors are not routinely tested for malaria before blood 
donation in China. Here, we reported that the prevalence 
of malaria antibodies was 2.13% among blood donors in 
Eastern China. We also showed the significant relationship 
between the prevalence of malaria antibodies and donor’s 
age. Individuals aging 46-60 years had the highest 
prevalence of malaria antibodies (6.86%), while individuals 
aging 18-25 years had a much lower prevalence (0.89%). 
Donors who were mobile workers had higher prevalence 
of malaria antibodies (2.81%) than university students 
(0.49%). This could be attributed to their work environment 
with higher exposure to mosquitoes. We recorded the lowest 
prevalence of malaria antibodies in Chinese university 
students; most of these subjects had never even heard of 
malaria or Plasmodium. In Jiangsu, the first-time blood 
donors are predominant (> 70%) and, thus, it was not 
surprising that the prevalence of malaria antibodies in 
first-time donors was higher than that in those who had 
donated before. 
The risk of TTM differs widely in non-endemic 
countries, where imported infection occurs in individuals 
who have traveled to or migrated from endemic regions8. 
Therefore, blood donors were screened for malaria 
antibodies to identify those at risk for malaria in many 
non-endemic areas. The English transfusion service9 has 
been screening blood donors for over 10 years. From 2010 
to 2013, 138,782 donations were identified as being at risk 
for malaria and screened for malaria antibodies. Of these, 
4,302 (3.1%) were reactive to the primary malarial antibody, 
and malaria DNA was found in 14 of 1,955 samples 
investigated. In Australia10, of 154,804 samples screened, 
7,055 (4.56%) were initially reactive and 6,786 (4.38%) 
were reactive in the repeated tests. One tested positive in the 
PCR assay and showed a very low level of parasitemia. In 
Switzerland11, 12,887 donors, who had traveled to regions 
at risk for malaria, were screened for antibodies against the 
Plasmodium species. Of these samples, 1,011 were reactive 
and a further 152 fell within the gray zone of the assay. 
The prevalence of malaria antibodies was 9.02%. Between 
2005 and 2011 in the USA12, 103 (1.84%) samples were 
found to be initially reactive and 88 (1.57%) were reactive 
in the repeated test for malaria antibodies in 5,610 donors 
at risk for malaria; none was tested positive for malaria 
DNA. In India13, the prevalence of malaria antibodies 
in eligible donors was 16.9%. None of the donors was 
positive for malaria on microscopic examination. In our 
investigation, blood donors were selected according to their 
ID numbers from different provinces. Most of them came 
from historically endemic provinces. The donors did not 
report their medical histories, and most of them were not 
at risk for malaria. This is the reason for the low prevalence 
(2.13%) of malaria antibodies in our subjects, compared to 
those of other countries. Other reasons for the prevalence 
variation might be differences in climate, environmental 
factors, endemic status of the region, and the EIA kits used.
There are different strategies for reducing the risk of 
TTM. These include screening the blood donors using 
questionnaires or by direct parasite detection, antibody/
antigen testing, and nucleic acid testing. Microscopy is 
a reference method to diagnose malaria parasitemia in 
endemic areas, but it cannot identify “semi-immune” donors 
with a very low level of parasitemia. Moreover, microscopic 
techniques are inappropriate for universal screening of 
blood donors because it is time-consuming and requires 
significant expertise and specialized equipment. In endemic 
countries, the detection of plasmodial DNA by PCR has 
been suggested as a method to screen infectious donations 
with low parasitemia doses14,15. Retrospective analyses of 
implicated donors have confirmed the presence of high 
titers of antibodies in these individuals16. The method used 
in this study demonstrated sufficiently high sensitivity and 
specificity to screen at-risk donors in non-endemic areas, 
but cannot be used to diagnose acute malarial infection. 
Moreover, a negative result in the malaria antibody test 
cannot guarantee that the donor is not infected. It may also 
result in the unnecessary rejection of donors. 
Our results illustrated that the prevalence of malaria 
antibodies was no higher than expected, even in donors from 
regions where malaria is endemic. Additionally, parasitemia 
was not detected even once, and none tested positive for 
Plasmodium DNA in the PCR assay. The number of blood 
donors is estimated to be less than 1% of the total national 
population. Donor deferral will further reduce repeat 
donations and universal serological screening is impossible. 
In this study, follow-up investigations were not conducted, 
and none of the donors was deferred. Hence, the deferral of 
malaria-risk donors still relies on the deferral guidelines, 
and, for a long time, this has been the only method to prevent 
TTM in China. Donors may give inaccurate information 
intentionally or unintentionally because they misunderstand 
the questions or are unaware or have forgotten that they 
have previously had contact with malaria. Thus, it would 
not be sufficient to prevent TTM by questionnaires17,18. 
Considering the limitations and cost of screening reagents 
and methods, setting up appropriate deferral strategies can 
reduce the risk of TTM to a minimum, providing that they 
could be properly applied. This can also be achieved by 
improving the quality of the questionnaire and the interview 
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techniques, and may require carefully explaining the risk 
of malaria infection to the donors. Further investigations 
are of importance to provide elaborate data that might help 
the authorities to make better-informed decisions regarding 
donor deferrals.
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